

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/212697 A1

(51) International Patent Classification:

C07K 14/54 (2006.01) C07K 14/705 (2006.01)
A61P 35/00 (2006.01) C07K 14/715 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2023/066367

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,025 28 April 2022 (28.04.2022) US

(71) Applicant: IMMATICS US, INC. [US/US]; 2201 W. Holcombe Blvd, Suite 205, Houston, Texas 77030 (US).

(72) Inventors: GUNESCH, Justin; 2201 W. Holcombe Blvd., Suite 205, Houston, Texas 77030 (US). HOSSAIN, Mohammad; 2201 W. Holcombe Blvd., Suite 205, Houston,

Texas 77030 (US). BAJWA, Gagan; 2201 W. Holcombe Blvd., Suite 205, Houston, Texas 77030 (US). MATA, Melinda; 2201 W. Holcombe Blvd., Suite 205, Houston, Texas 77030 (US). KALRA, Mamta; 2201 W. Holcombe Blvd., Suite 205, Houston, Texas 77030 (US).

(74) Agent: MCBEE, Susan E; McBee Moore & Vanik IP, LLC, 10 South Market Street, 2nd Floor, Frederick, Maryland 21701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: MEMBRANE-BOUND IL-15, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THERE-OF




FIG. 1

(57) Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors ("TCR") together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15R α , IL-15/IL-15R α fusion polypeptide, and IL-15R α /IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*